Work

Factors Linked to Injection Interval Extension in Eyes with Wet Age-Related Macular Degeneration Switched to Brolucizumab

Year: 2023

Type: article

Study design: Observational Study

Source: Ophthalmology

DOI: 10.1016/j.ophtha.2023.03.017

Authors: Mathew W. MacCumber, Charles C. Wykoff, Helene Karcher, Eser Adiguzel, Samriddhi Buxy Sinha, Saloni Vishwakarma, Andrew LaPrise, Franklin Igwe, Rita Freitas, Michael S. Ip, Marco A. Zarbin

Institutions: Rush University Medical Center, Illinois Retina Associates, Retina Consultants of Texas, Novartis (Switzerland), Novartis (United States), Sandoz Group AG (Switzerland), Novartis Farma SA (Portugal), University of California, Los Angeles, Doheny Eye Institute, Rutgers New Jersey Medical School

Language: English

Topic: Retinal Diseases and Treatments

Subfield: Ophthalmology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4361000164

FWCI: 2.166

Cites: 15

Cited by: 9

Related to: 10